Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea

BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting β(2)-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-mark...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Tuberc Respir Dis (Seoul)
Egile Nagusiak: Yum, Ho-Kee, Kim, Hak-Ryul, Chang, Yoon Soo, Shin, Kyeong-Cheol, Kim, Song, Oh, Yeon-Mok
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256353/
https://ncbi.nlm.nih.gov/pubmed/28119747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2017.80.1.52
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak